CD274 and cancer: Immunocytochemistry, on the other hand, is studied to evaluate cancer antigens, e.g., the expression of PD-L1 in the CTCs of NSCLC patients as an indication for treatment using PD-1/PD-L1 immune checkpoint inhibitors [38].